Abstracts tagged "polymyositis/dermatomyositis (PM/DM) and treatment"

Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Océane Landon-Cardinal¹, Perrine Guillaume-Jugnot ², Lois Bolko ², Ségolène Toquet ², Aude Rigolet ², Baptiste Hervier ³, Nicolas Champtiaux ², Mathieu VAUTIER ⁴, Olivier Benveniste ⁵ and Yves Allenbach ⁵, ¹Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ²Pitié-Salpêtrière University Hospital, Paris, France, ³Hopital Pitie-Salpetriere, Paris, France, ⁴Paris - Pitié salpétrière, Paris, France, ⁵Sorbonne Université, Paris, France
Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…
Abstract Number: 2055 • 2013 ACR/ARHP Annual Meeting
Killer T Cell Inhibition By CD226 Blockade For Treatment Of Inflammatory Myopathy
Hitoshi Kohsaka¹, Nao Tateishi¹, Shinya Hirata², Kazuko Shibuya³, Akira Shibuya³ and Nobuyuki Miyasaka⁴, ¹Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Kumamoto University School of Medicine, Kumamoto, Japan, ³Department of Immunology, University of Tsukuba, Ibaraki, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Current treatment strategy of polymyositis/dermatomyositis calls for administration of high dose glucocorticoids and additional immunosupressants when necessary. These options are based largely on successful…
Abstract Number: 2058 • 2013 ACR/ARHP Annual Meeting
Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review
Erin Vermaak¹ and Neil J McHugh^1,2, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronic inflammatory disorders of muscle. The morbidity and mortality associated with these conditions remains significant despite treatment,…
Abstract Number: 1946 • 2012 ACR/ARHP Annual Meeting
Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis
Ingela M. Loell¹, Yi-Wen Chen², Marina Korotkova³, Kanneboyina Nagaraju² and Ingrid E. Lundberg⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) muscle tissue is characterized by infiltrating T cells, macrophages and dendritic cells, as well as cytokines and chemokines. In…
Abstract Number: 757 • 2012 ACR/ARHP Annual Meeting
Beneficial Role of Rapamycin in Experimental Autoimmune Myositis
Nicolas Prevel¹, Yves Allenbach², David Klatzman¹, Benoit Salomon¹ and Olivier Benveniste³, ¹UPMC Université Paris 06, UMR 7211, Paris, France, ²Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ³Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose: Idiopathic inflammatory myopathies are a heterogeneous group of different diseases, classified into four main categories: dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body…
Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Kavish J. Bhansing¹, Piet LCM Van Riel², Sigrid Pillen³, Baziel G.M. van Engelen⁴ and Madelon C. Vonk⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Neurology, Catharina Wilhemina Hospital, Nijmegen, Netherlands, ⁴Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…
Abstract Number: 225 • 2012 ACR/ARHP Annual Meeting
Polymyositis in HIV+ Patients Is Associated to Uncontrolled Viral Load
Yves Allenbach¹, Odile Dubourg², Thierry Maisonobe², Anthony Behin³, Charles Duyckaerts², Guillaume Breton⁴, Olivier Fain⁵, Marie-Caroline Meyhoas⁶, Catherine Leport⁷, Marc-Antoine Valentin⁸, Daniel Vittecoq⁹, Jean-François Bergmann¹⁰, Thomas Anslik¹¹, Marie-Paule Chauveheid¹², Zahir Amoura¹³, Thomas de Broucker¹⁴, Pierre Bourgeois¹⁵, Bruno Eymard³, Serge Herson¹⁶ and Olivier Benveniste¹⁷, ¹Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ²Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ³Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, ⁴Internal Medecine, Pitie-Salpetriere Hospital, Paris, France, ⁵Internal Medicine, Jean Verdier Hospital, Bondy, France, ⁶Department of Infectious Diseases, Saint Antoine Hospital, Paris, France, ⁷Epidemic and biological risk coordination unit, AP-HP, Paris, France, ⁸Department of Infectious Diseases, Pitié-Salpetriere Hospital, Paris, France, ⁹Department of Infectious Diseases, K Bicetre Hospital, Kremlin-Bicetre, France, ¹⁰Internal Medicine, Lariboisiere Hospital, Paris, France, ¹¹Internal Medicine, Ambroise Pare Hospital, Boulogne Billancourt, France, ¹²Internal Medicine,, University Paris-7, APHP, Bichat Hospital, Paris, France, ¹³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹⁴Department of Neurology, Delafontaine Hospital, Saint Denis, France, ¹⁵Rheumatology, APHP,Pitie-Salpetriere Hospital, Paris 6, Paris, France, ¹⁶Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ¹⁷Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose: Different myopathies can be observed in HIV-infected patients, such as idiopathic inflammatory myopathies (inclusion-body myositis or polymyositis) or toxic mitochondrial myopathies secondary to antiretroviral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].